ALOX5AP is an Indicator for High CD8 Lymphocyte Infiltration and "Hot" Tumor Microenvironment in Osteosarcoma: A Bioinformatic Study
- PMID: 37041365
- DOI: 10.1007/s10528-023-10374-0
ALOX5AP is an Indicator for High CD8 Lymphocyte Infiltration and "Hot" Tumor Microenvironment in Osteosarcoma: A Bioinformatic Study
Abstract
Little progress has been made in the treatment and prognosis of osteosarcoma in the past 40 years. Tumor microenvironment (TME) plays a critical role in the progression of osteosarcoma. This study aims to determine immune-associated prognostic biomarkers for osteosarcoma patients. With the help of analytical tools including ESTIMATE, differential gene expression, LASSO, and univariate cox and multivariate cox regression analysis, osteosarcoma gene expression data from Gene Expression Omnibus (GEO) databases were investigated. Following the establishment of a prognostic risk score model, internal and external validations using the GEO and TARGET databases were carried out. A total of 44 and 55 samples respectively in the GSE21257 and the TARGET databases were included. Our analysis found 93 differentially expressed genes (DEGs) between the high and low-ImmuneScore groups. Through univariate cox and LASSO analysis, ALOX5AP was identified as an indicator of TME in osteosarcomas. ALOX5AP was then used to construct a prognostic risk model. Internal and external verification revealed that higher expression of ALOX5AP was correlated with lower risk. Through the CIBERSORT algorithm, the level of CD8 T cells was found to negatively correlate with the risk score. This study revealed that ALOX5AP is an indicator for predicting high CD8 lymphocyte infiltration and "hot" tumor microenvironment in osteosarcomas. Thus, ALOX5AP has the potential to act as a biomarker for effective immunotherapies in osteosarcoma patients.
Keywords: Bioinformatics; Biomarker; Osteosarcoma; Tumor microenvironment.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Construction and validation of a lipid metabolism-related genes prognostic signature for skin cutaneous melanoma.Biochem Biophys Res Commun. 2025 Aug 15;775:152115. doi: 10.1016/j.bbrc.2025.152115. Epub 2025 May 29. Biochem Biophys Res Commun. 2025. PMID: 40460484
-
Multomic analysis reveals the potential of LAG3 as a prognostic and immune biomarker and its validation in osteosarcoma.Sci Rep. 2025 Jul 11;15(1):25158. doi: 10.1038/s41598-025-10290-w. Sci Rep. 2025. PMID: 40646089 Free PMC article.
-
An immune-related gene signature for determining Ewing sarcoma prognosis based on machine learning.J Cancer Res Clin Oncol. 2021 Jan;147(1):153-165. doi: 10.1007/s00432-020-03396-3. Epub 2020 Sep 23. J Cancer Res Clin Oncol. 2021. PMID: 32968877 Free PMC article.
-
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340. Health Technol Assess. 2006. PMID: 16959170
-
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].Epidemiol Prev. 2013 Mar-Jun;37(2-3 Suppl 2):1-100. Epidemiol Prev. 2013. PMID: 23851286 Italian.
Cited by
-
Engineering sonogenetic EchoBack-CAR T cells.Cell. 2025 May 15;188(10):2621-2636.e20. doi: 10.1016/j.cell.2025.02.035. Epub 2025 Apr 2. Cell. 2025. PMID: 40179881
-
Role of the CTCF binding site in Human T-Cell Leukemia Virus-1 pathogenesis.PLoS Pathog. 2025 Jun 3;21(6):e1012293. doi: 10.1371/journal.ppat.1012293. eCollection 2025 Jun. PLoS Pathog. 2025. PMID: 40460345 Free PMC article.
-
ALOX5AP suppresses osteosarcoma progression via Wnt/β-catenin/EMT pathway and associates with clinical prognosis and immune infiltration.J Orthop Surg Res. 2023 Jun 22;18(1):446. doi: 10.1186/s13018-023-03919-x. J Orthop Surg Res. 2023. PMID: 37344882 Free PMC article.
-
Role of the CTCF Binding Site in Human T-Cell Leukemia Virus-1 Pathogenesis.bioRxiv [Preprint]. 2024 May 28:2024.05.28.596170. doi: 10.1101/2024.05.28.596170. bioRxiv. 2024. Update in: PLoS Pathog. 2025 Jun 3;21(6):e1012293. doi: 10.1371/journal.ppat.1012293. PMID: 38853836 Free PMC article. Updated. Preprint.
-
The Prognostic Impact of the Tumor Immune Microenvironment in Synovial Sarcoma: An Immunohistochemical Analysis Using Digital Pathology and Conventional Interpretation.J Pers Med. 2025 Apr 25;15(5):169. doi: 10.3390/jpm15050169. J Pers Med. 2025. PMID: 40423041 Free PMC article.
References
-
- Bäck M, Sultan A, Ovchinnikova O, Hansson GK (2007) 5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation. Circ Res 100(7):946–949. https://doi.org/10.1161/01.RES.0000264498.60702.0d - DOI - PubMed
-
- Behjati S, Tarpey PS, Haase K, Ye H, Young MD, Alexandrov LB, Farndon SJ, Collord G, Wedge DC, Martincorena I, Cooke SL, Davies H, Mifsud W, Lidgren M, Martin S, Latimer C, Maddison M, Butler AP, Teague JW, Pillay N, Shlien A, McDermott U, Futreal PA, Baumhoer D, Zaikova O, Bjerkehagen B, Myklebost O, Amary MF, Tirabosco R, Van Loo P, Stratton MR, Flanagan AM, Campbell PJ (2017) Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma. Nat Commun 8:15936. https://doi.org/10.1038/ncomms15936 - DOI - PubMed - PMC
-
- Cao M, Zhang J, Xu H, Lin Z, Chang H, Wang Y, Huang X, Chen X, Wang H, Song Y (2020) Identification and development of a novel 4-gene immune-related signature to predict osteosarcoma prognosis. Front Mol Biosci 7:608368. https://doi.org/10.3389/fmolb.2020.608368 - DOI - PubMed - PMC
-
- Chen X, Bahrami A, Pappo A, Easton J, Dalton J, Hedlund E, Ellison D, Shurtleff S, Wu G, Wei L, Parker M, Rusch M, Nagahawatte P, Wu J, Mao S, Boggs K, Mulder H, Yergeau D, Lu C, Ding L, Edmonson M, Qu C, Wang J, Li Y, Navid F, Daw NC, Mardis ER, Wilson RK, Downing JR, Zhang J, Dyer MA (2014) Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep 7(1):104–112. https://doi.org/10.1016/j.celrep.2014.03.003 - DOI - PubMed - PMC
-
- Codreanu SG, Hoeksema MD, Slebos RJC, Zimmerman LJ, Rahman SMJ, Li M, Chen SC, Chen H, Eisenberg R, Liebler DC, Massion PP (2017) Identification of proteomic features to distinguish benign pulmonary nodules from lung adenocarcinoma. J Proteome Res 16(9):3266–3276. https://doi.org/10.1021/acs.jproteome.7b00245 - DOI - PubMed - PMC
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous